1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE
5.1. Introduction
5.2. Diagnostic Testing
5.3. Pharmacological Drugs
5.4. Surgical Treatment
6. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY DRUG TYPE
6.1. Introduction
6.2. Pirfenidone
6.3. Nintedanib
6.4. Others
7. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.2. Oral
7.3. Parenteral
8. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY END-USE
8.1. Introduction
8.2. Hospitals and Clinics
8.3. Ambulatory Surgical Centers
8.4. Others
9. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. United States
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. United Kingdom
9.4.2. Germany
9.4.3. France
9.4.4. Spain
9.4.5. Others
9.5. Middle East & Africa
9.5.1. Saudi Arabia
9.5.2. Israel
9.5.3. UAE
9.5.4. Others
9.6. Asia Pacific
9.6.1. Japan
9.6.2. China
9.6.3. India
9.6.4. South Korea
9.6.5. Indonesia
9.6.6. Thailand
9.6.7. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Roche Holding AG
11.2. Boehringer Ingelheim
11.3. AdAlta
11.4. FibroGen, Inc.
11.5. United Therapeutics
11.6. Galecto Biotech
12. APPENDIX
12.1. Currency
12.2. Assumptions
12.3. Base and Forecast Years Timeline
12.4. Key benefits for the stakeholders
12.5. Research Methodology
12.6. Abbreviations